Results 31 to 40 of about 21,293 (203)

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [PDF]

, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic ...
Ajana, F, Arribas, JR, Bailey, J, Benson, P, Berenguer, J, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brown, Kimberley, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, Cunningham, Douglas, de Vente, J, De Wit, S, De Wit, Stéphane, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Eron, Joseph J, Fehr, J, Felizarta, F, Fichtenbaum, C, Flamholc, L, Florence, E, Galindo, MJ, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girardy, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Hufkens, Veerle, Huhn, G, Iribarren, JA, Jain, M, Jezorwski, John, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lathouwers, Erkki, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Opsomer, Magda, Orkin, C, Orkin, Chloe, Osiyemi, O, Perez-Valero, I, Petrovic, Romana, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Post, F, Post, Frank A, Prelutsky, D, Pulido, F, Pulido, Federico, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Santos Gil, I, Scarsella, A, Scribner, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Teicher, E, Thalme, A, Ustianowski, A, Van Landuyt, Erika, Van Wijngaerden, E, Vandekerckhove, Linos, Vandercam, B, Voskuhl, G, Walmsley, S, Ward, D, Waters, L, Wilkin, A, Witor, A, Yazdanpanah, Y   +118 more
core   +2 more sources

The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV

Journal of Virus Eradication, 2021
This article evaluates the evidence supporting use of the tenofovir disoproxil fumarate (TDF) plus lamivudine (3​TC) combination as a dual nucleoside backbone within a triple drug antiretroviral regimen.
Laura Waters, Viraj Mehta, Jaideep Gogtay, Marta Boffito   +3 more
doaj   +1 more source

A case of fatal acute kidney failure and anion gap metabolic acidosis in human immunodeficiency virus patient receiving tenofovir disoproxil fumarate

Heliyon
Tenofovir disoproxil fumarate, is the prodrug of tenofovir, a nucleotide analogue reverse transcriptase inhibitors used to treat human immunodeficiency virus infection. Tenofovir disoproxil fumarate is the antiretroviral most associated with acute kidney
Nata Pratama Hardjo Lugito, Margaret Merlyn Tjiang, Jeremia Immanuel Siregar, Raoulian Irfon, Andhica Saputri   +4 more
doaj   +1 more source

Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday

Molecules, 2021
Nucleoside and nucleotide analogues are essential antivirals in the treatment of infectious diseases such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus (HSV), varicella-zoster virus (VZV ...
Guangdi Li, Tingting Yue, Pan Zhang, Weijie Gu, Ling-Jie Gao, Li Tan   +5 more
doaj   +1 more source

Tenofovir disoproxil fumarate for preventing mother-to-child transmission of hepatitis B: a literature review

Clinical and Experimental Obstetrics & Gynecology, 2021
Infection with the hepatitis B virus (HBV) is one of the leading global public health issues. Over 250 million people worldwide have chronic HBV infection, out of which roughly 65 million are women in their reproductive age.
Iulia Baciu, Dalila-Ana Domuncu, Tiberiu Domuncu, AncaMarina Ciobanu, Theodor Voiosu, Gheorghe Peltecu, AncaMaria Panaitescu   +6 more
doaj   +1 more source

Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. [PDF]

, 2011
The latest World Health Organization guidelines recommend replacing stavudine with tenofovir or zidovudine in first-line antiretroviral therapy in resource-limited settings.
Birkus, Brinkman, Callaghan, Cohen, Davidson, Ford, Gallant, Gallant, Grim, Hawkins, Mills, Pozniak, Stone   +12 more
core   +2 more sources

Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis

Antiviral Therapy, 2022
Tenofovir-based pre-exposure prophylaxis (PrEP) revolutionized the global HIV prevention landscape. Prior to the proof-of concept trial in 2010, which demonstrated that tenofovir (TFV) could prevent sexual transmission of HIV, prevention options were ...
Salim S Abdool Karim, Cheryl Baxter, Quarraisha Abdool Karim   +2 more
doaj   +1 more source

Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW). [PDF]

, 2016
We conducted a longitudinal and cross-sectional analysis of depressive symptomology in iPrEx, a randomized, placebo-controlled trial of daily, oral FTC/TDF HIV pre-exposure prophylaxis (PrEP) in men and transgender women who have sex with men. Depression-
Amico, K Rivet, Avelino-Silva, Vivian I, Burns, David, Chodacki, Piotr, Defechereux, Patricia A, Fernandez, Telmo, Glidden, David V, Grant, Robert M, iPrEx Study Team, Liu, Albert Y, Mayer, Kenneth H, McMahan, Vanessa M, Mehrotra, Megha, Vargas, Lorena   +13 more
core   +1 more source

Guides concerning tenofovir exposure via breastfeeding: A comparison of drug dosages by developmental stage

International Journal of Infectious Diseases, 2019
Tenofovir disoproxil fumarate (TDF) is a prodrug of tenofovir, and after being administered orally, it converts to tenofovir in the blood. With the increasing use of TDF in women for treatment and prevention of mother-to-child transmission (MTCT) of both
Xiaotong Hu, Liming Wang, Fujie Xu
doaj   +1 more source

The Safety of Interferon‐Based Therapies in Chronic Hepatitis B Patients With Compensatory Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
While nucleos(t)ide analog (Nuc) therapy is the standard for chronic hepatitis B, pegylated interferon‐alpha (Peg‐IFN‐α) provides unique advantages, including finite treatment duration and long‐term benefits. However, its use in patients with compensated cirrhosis remains limited due to persistent safety concerns about potential decompensation and ...
Qiran Zhang, Taoran Geng, Ruirui You, Huiling Xiang, Ying Guo, Xiaohong Gao, Guojun Li, Qun Zhang, Xiaoping Wu, Haifang Cao, Wenhua Zhang, Jia Shang, Jiawei Geng, Lihong Qu, Shuilin Sun, Xiulan Xue, Rui Zhao, Lihua Zhong, Guohong Ge, Yanbin Wang, Jianqi Lian, Ming Liang, Qing Ye, Xiaoyan Wang, Xiaoqing Guo, Dan Xu, Yiqi Yu, Feng Sun, Chao Qiu, Jiming Zhang, Yuxian Huang, Wenhong Zhang, Xiaolong Qi   +32 more
wiley   +1 more source